西亚试剂：Vaccination with Human Pluripotent Stem Cells Generates a B

发布时间：2026-01-28

Vaccination with Human Pluripotent Stem Cells Generates a Broad Spectrum of Immunological and Clinical Response against Colon Cancer

Yi Li 1 4, Hui Zeng 2 3 5, Ren-He Xu 2 3, Bei Liu 1 2 *, Zihai Li 1 2 *

1Department of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030-1601
2UConn Stem Cell Institute, University of Connecticut School of Medicine, Farmington, CT 06030-1601
3Department of Genetics and Developmental Biology, University of Connecticut School of Medicine, Farmington, CT 06030-1601
4Department of Gynecology and Obstetrics, Peking University People's Hospital, 100044 Beijing, China
5Department of Hematology, Xiang-Ya Hospital, Central South University, Changsha, Hunan 410008, China

The history of immunizing with embryonic materials to generate an anti-tumor immune response dates back a century ago. The premise is that cancer cells share the expression of oncofetal antigens with embryonic materials and that the immune response against these antigens in the embryonic tissues is cross-protective against cancer. However, such a practice has never advanced beyond experimental animal settings, due to lack of uniformed source tissues and ethical challenges. With the availability of well-characterized human pluripotent stem cells, it is now possible to ask if tumor protective immunity could indeed be elicited with stem cells. Herein, we investigated if vaccination with defined human embryonic stem (hES) or induced pluripotent stem (iPS) cells was effective against a colon carcinoma. We discovered that vaccination of mice with hES cell line H9 generated consistent cellular and humoral immune responses against CT26 colon carcinoma. Protection correlated strongly with the expansion of tumor-responsive and interferon -producing cells and the profound loss of CD11b+Gr-1+ myeloid derived suppressor cells in the spleen. No evidence of autoimmunity was observed. We also compared the immunogenicity against colon cancer between a hES cell line CT2 and an iPS cell line TZ1 that were generated in the same stem cell facility. We found that the iPS cell line was inferior to the hES cell line in conferring tumor protection, suggesting that there is heterogeneity of expression of oncofetal antigens by hES and iPS cells. We conclude that the hES-based vaccine is a promising modality for immunotherapy of cancer.

• 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   
• 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇 等均有销售.欢迎订购

 

上一篇：7-氟吲哚满二酮
下一篇：西亚试剂：现代煤化工：国家战略筹码